1. Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization
- Author
-
Päivi M. Ojala, Michael Jeltsch, Kari Alitalo, Wei Zheng, Hanna Heloterä, Tanja Holopainen, Simonas Laurinavičius, Tuomas Tammela, Denis Tvorogov, Nisse Kalkkinen, Andrey Anisimov, Wolfgang Holnthoner, Veli-Matti Leppänen, Hilkka Lankinen, Tvorogov, Denis, Anisimov, Andrey, Zheng, Wei, Leppanen, Veli-Matti, Tammela, Tuomas, Laurinavicius, Simonas, Holnthoner, Wolfgang, Helotera, Hanna, Holopainen, Tanja, Jeltsch, Michael, Kalkkinen, Nisse, Lankinen, Hikka, Ojala, Päivi M, and Alitalo, Kari
- Subjects
Cancer Research ,medicine.drug_class ,Receptor, ErbB-2 ,government.form_of_government ,ligand binding ,Vascular Endothelial Growth Factor C ,lymphatic endothelium ,Angiogenesis Inhibitors ,Biology ,Monoclonal antibody ,Article ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Morphogenesis ,Humans ,Receptor ,Cells, Cultured ,030304 developmental biology ,0303 health sciences ,vascularisation ,Antibodies, Monoclonal ,Cell Biology ,medicine.disease ,Vascular Endothelial Growth Factor Receptor-3 ,Molecular biology ,Vascular Endothelial Growth Factor Receptor-2 ,3. Good health ,Vascular endothelial growth factor ,Lymphatic Endothelium ,chemistry ,Vascular endothelial growth factor C ,Oncology ,030220 oncology & carcinogenesis ,embryonic structures ,Cancer research ,government ,biology.protein ,cardiovascular system ,Antibody ,Signal transduction ,Protein Multimerization - Abstract
Antibodies that block vascular endothelial growth factor (VEGF) have become an integral part of antiangiogenic tumor therapy, and antibodies targeting other VEGFs and receptors (VEGFRs) are in clinical trials. Typically receptor-blocking antibodies are targeted to the VEGFR ligand-binding site. Here we describe a monoclonal antibody that inhibits VEGFR-3 homodimer and VEGFR-3/VEGFR-2 heterodimer formation, signal transduction, as well as ligand-induced migration and sprouting of microvascular endothelial cells. Importantly, we show that combined use of antibodies blocking ligand binding and receptor dimerization improves VEGFR inhibition and results in stronger inhibition of endothelial sprouting and vascular network formation in vivo. These results suggest that receptor dimerization inhibitors could be used to enhance antiangiogenic activity of antibodies blocking ligand binding in tumor therapy. Refereed/Peer-reviewed
- Published
- 2010
- Full Text
- View/download PDF